Episode Details
Back to Episodes
William Blair Senior Biotech Analyst Andy Hsieh shares an overview of the obesity space heading into 2026
Published 8 months, 2 weeks ago
Description
He discusses the recently approved Wegovy pill, and compares and contrasts it to other oral programs from Lilly, Structure, and Corbus. Plus, how is the amylin space looking compared to GLP-1s, and a preview of Viking's 2026.